Articles tagged with Glioblastomas
Researchers at Stanford University School of Medicine found that a subgroup of glioblastoma patients with highly vascularized tumors benefited from anti-angiogenic therapies, living an average of one year longer than those without. The study highlights the importance of properly categorizing tumors to personalize treatment.
A new biomarker enzyme ALDH1A3 has been identified in mesenchymal glioma stem-like cells, which are responsible for the tumorigenicity of glioblastoma multiforme tumors. The researchers have developed a small molecule inhibitor GA11 that targets this enzyme and has shown potent efficacy in preclinical testing.
Scientists identified a gene NAMPT that fuels glioblastoma growth and resistance to radiation therapy. Inhibiting NAMPT may improve treatment outcomes for most aggressive forms of the disease.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified the functional role of two distinct DNA modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5-hmC), in glioblastoma tissues. The study found that 5hmC signatures had a strong association with patient survival.
Researchers at MD Anderson Cancer Center identified a pathway by which cancer cells spread in the brain, opening up new possibilities for treatment. They found that the gene WNT5A enables glioma stem cells to transition into GdECs, leading to aggressive tumor growth and disease recurrence.
A study by Ludwig Cancer Research identified a metabolic vulnerability in glioblastoma cells that can be exploited for therapy. GBM cells are extremely dependent on imported cholesterol and shutting down their import controls leads to dramatic cancer cell death and tumor shrinkage.
Researchers found that depriving brain tumor cells of cholesterol specifically kills them and causes tumor regression. This alternative method targets glioblastomas, the most aggressive form of brain cancer, which are difficult to treat due to their biochemical composition and blood-brain barrier.
Researchers have created a new method to combat glioblastomas, a type of brain tumor that is difficult to treat. The method involves testing multiple substances on individual cancer cells from each patient and identifying effective combinations for treatment.
A study published in Neurosurgical Focus reports the use of a minimally invasive laser procedure to treat large, 'inoperable' brain tumors, including glioblastomas. The procedure combines laser interstitial thermotherapy with a small craniotomy to remove cooked tumors and prevent swelling.
Researchers discovered that glioblastoma cells inhibit caspase-3 activity in microglia, leading to a tumor-stimulating phenotype. This inhibition causes microglia to stimulate tumor cells instead of attacking them.
Systems biologist Jan Philipp Junker and molecular geneticist Gaetano Gargiulo have each received a €1.5 million ERC Starting Grant to study cellular processes in zebrafish and glioblastoma, respectively. Their research aims to understand the mechanisms behind variable phenomena in developmental biology.
Researchers found that immune checkpoint blockade improved survival and promoted immune cell infiltration into tumors when combined with an antitumor vaccine. The study suggests PD-1 and PD-L1 may help tumors evade vaccines, supporting testing of therapeutic combinations in clinical trials.
The extent of resection in glioblastoma patients was found to be associated with improved overall and progression-free survival. Glioblastoma multiforme (GBM) patients who underwent gross total resection (GTR) showed a significant increase in one-year and two-year survival rates compared to those with subtotal resection or biopsy.
Researchers from UH Seidman Cancer Center will present data on a new online tool for estimating individualized survival probabilities in patients with newly diagnosed glioblastoma. The studies also explore promising new treatments, including pembrolizumab for head and neck squamous cell carcinoma, and improve patient participation in c...
Researchers have identified a group of immune system genes associated with glioblastoma multiforme survival. The eight-gene signature is linked to shorter survival times and more rapid disease progression, but may also identify potential targets for treatment.
Researchers identified a specific enzyme and signaling pathway involved in resistance to treatment, which can be targeted by other drugs for improved outcomes. Glioblastoma multiforme tumors were shown to manipulate their surrounding environment to evade therapy, leading to longer survival when treated with combination therapies.
A clinical study reveals that glioblastoma subtypes develop in distinct brain regions, shedding light on the origins of these aggressive brain cancers. The discovery may lead to more effective personalized treatment approaches by identifying specific subtype markers.
A gene known as OSMR plays a key role in driving the growth of glioblastoma tumors, according to a new study. Researchers discovered that by disabling OSMR, glioblastoma cells lose their ability to form tumors in mice, suggesting a potential target for treatments.
A team of researchers has identified an alternate mechanism for evading therapy in brain cancer cells, which adapts within as little as three days of treatment. By targeting both the original and new signaling pathways, they can durably suppress tumor growth.
Two studies from Massachusetts General Hospital suggest that targeting both VEGF and Ang-2 pathways can normalize tumor blood vessels and shift immune cells towards an anti-tumor state. This approach has shown promise in slowing glioblastoma growth and improving survival rates.
Researchers at Ohio State University Wexner Medical Center have identified altered metabolism of methionine and tryptophan as a driving force behind glioblastoma progression. Restricting dietary intake of these amino acids may slow tumor growth and improve treatment outcomes.
Glioblastoma patients with high BIRC3 expression have shorter overall survival rates, while those with low expression live longer. Analyzing BIRC3 tissue levels could help detect treatment resistance earlier.
Researchers at Nagoya University developed a novel immunotherapy using genetically engineered T cells that target podoplanin, a key protein associated with GBM progression. This treatment successfully arrested tumor growth in 60% of mice and demonstrated promise for treating patients with relapsed or resistant tumors.
Researchers identified SGEF as a target for new brain cancer therapies in a study published by Molecular Cancer Research. The protein promotes the survival of glioblastoma tumor cells and helps the cancer invade brain tissue.
Researchers at Salk Institute identify nuclear factor kB as a key player in glioblastoma multiforme proliferation. Targeting this protein with NBD peptide or Timp1 gene slows tumor growth and increases mouse survival time, offering potential new treatment avenues.
Researchers found that combining TTFields with chemotherapy significantly improved progression-free and overall survival for patients with glioblastoma. The study, published in JAMA, suggests a potential new treatment approach for this devastating brain tumor.
The EORTC trial 26101 found that bevacizumab treatment in progressive glioblastoma patients did not confer a survival advantage despite prolonged progression-free survival. The combination of bevacizumab and lomustine may prolong PFS but does not impact overall survival.
Researchers develop nanoparticles that can carry therapeutics across the brain blood barrier, offering new hope for treating glioblastoma multiforme. The 3HM nanocarriers show promising attributes for treating brain cancers.
A new study funded by The Ben & Catherine Ivy Foundation has identified propentofylline as a potential drug that could help treat glioblastoma multiforme (GBM), a deadly brain tumor. The research found that PPF can limit the spread of GBM and increase the effectiveness of chemotherapy drugs and radiation therapy.
Researchers at University of California - San Diego developed a new computational strategy to search for molecules that could inhibit glioblastoma growth. One molecule, SKOG102, successfully shrunk human glioblastoma tumors grown in mouse models by an average of 50 percent.
A study found that low BRCA1 protein expression in glioblastoma tumors correlates with longer overall survival, suggesting a potential predictive biomarker for treatment responses to DNA-damaging therapies.
A team of researchers has mapped the connections between genetic mutations and protein regulation in glioblastoma multiforme (GBM) brain cancer. They found that targeting specific transcription factors, such as SOX9 and FOXG1, could potentially treat GBM using BET bromodomain inhibitors.
A Phase 2 clinical trial found that gene therapy VB-111 increased overall survival to 15 months, compared to 8 months for those receiving chemotherapy Avastin alone. The therapy effectively starves tumors by blocking new blood vessel growth and is safe and well-tolerated.
Scientists at Van Andel Research Institute and University of Toledo have discovered a way to stop the spread of glioblastoma multiforme by activating a family of proteins. This innovative approach may lead to a novel treatment for this deadly brain cancer, which affects 22,000 people in the US each year.
Researchers have developed a new therapy that slows the spread of deadly brain tumor cells by disrupting their communication pathway. The treatment improved patient survival by 50% in a mouse model and has potential as an adjunct to traditional chemotherapy and radiation treatments.
Researchers found an enzyme called LSD1 turns off genes required to maintain cancer stem cell properties in glioblastoma. Drugs modifying LSD1 levels could provide a new approach to treating the disease.
V-Smart Nanomedicine for glioblastoma multiforme (GBM) will target and deliver a known chemotherapeutic across the blood brain barrier, providing an effective new treatment option. The grant supports the development of this transformative therapeutic for brain cancer patients.
A national cancer study has found that a tumor's DNA, not just tumor stage, is key to determining if a lower-grade malignant brain tumor may rapidly progress to glioblastoma. The findings could lead to earlier and more aggressive treatment for those tumors projected to be on the fast path.
The Ivy Glioblastoma Atlas Project provides valuable resources for researchers to find cures for aggressive brain cancers, offering detailed information about genes and tumor formation. The atlas aims to advance understanding of glioblastoma biology and lead to novel approaches to improve treatment and survival.
Researchers developed a combinatorial approach to treating glioblastoma by combining three classes of anti-cancer drugs. The study found that a combination of EGFR inhibitor, PLK1 inhibitor and DNA-damaging agent effectively halted tumor growth in mouse models and human glioblastoma tissue.
The study provides a comprehensive look at glioblastoma treatments, reviewing challenges faced by researchers and clinicians. It presents hope for better treatments through harnessing the power of the human genome.
Researchers have discovered a key role played by IGFBP2 in regulating the action of EGFR in glioblastoma cells, allowing them to become resistant to drug treatments. This finding offers new hope for developing targeted therapies that target both EGFR and IGFBP2.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
Glioblastoma's aggressive nature is fueled by mTOR-induced pathways, but mTOR inhibitors have shown limited effectiveness. Compensatory glutamine metabolism plays a crucial role in mTOR inhibitor resistance, as evidenced by increased glutaminase and glutamine levels in GBM cells and tumor xenografts.
Researchers have discovered a way to boost the effectiveness of immunotherapy in treating glioblastoma by enhancing dendritic cell migration. This approach increased patient survival rates by over 36 months compared to traditional dendritic cell-based therapy alone.
Researchers at Moffitt Cancer Center have identified a key protein signaling pathway involved in the growth and survival of brain tumor stem cells. The neurotrophin pathway controls nerve growth, survival and specialization, and inhibiting TrkB and TrkC receptors can decrease stem cell survival.
A preclinical study by the University of Pennsylvania School of Medicine found engineered T cells to be both safe and effective at controlling tumor growth in mice with glioblastoma. The CAR T cells target a mutation in the epidermal growth factor receptor protein called EGFRvIII, found on about 30% of glioblastoma patients' tumor cells.
Researchers at UC San Diego identified a pyramid hierarchical network of coherent gene modules that regulate glioblastoma genes, involved in highly aggressive brain cancer. This finding informs a strategy to elucidate these modules and identify new drug therapies.
Researchers at Ohio State University identified three genes that enable glioblastoma stem-like cells to survive radiation therapy. MELK and EZH2 proteins form a complex that drives EZH2 expression, promoting tumor development and progression.
Researchers aim to eradicate glioblastomas by delivering the wound-healing peptide ACT1 to cancer cells via a virus. This approach has shown promising results in reducing tumor growth and increasing sensitivity to TMZ. The goal is to develop a novel therapy that can improve treatment outcomes for brain cancer patients.
Research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. High expression of PDL1 is common in both glioblastoma and brain metastases, making immune checkpoint inhibitors a promising treatment option.
Researchers have made a breakthrough in brain cancer treatment by identifying a key process that can be targeted with a new drug, AZD8055, which combines with Temozolomide to extend animal life by 30%. This discovery is leading to the start of a human phase I/II clinical trial as early as Spring 2015.
Researchers have discovered a fusion protein in approximately 15% of secondary glioblastomas, offering insights into the disease's cause and potential therapeutic targets. The PTPRZ-MET fusion may be exquisitely sensitive to existing MET inhibitors, allowing for personalized oncologic care.
A CTRC doctor has been awarded a $1.6 million FDA orphan grant to study the efficacy of TH-302 in treating glioblastoma, a devastating brain tumor with a median survival time of four months. The drug, combined with Avastin, aims to slow tumor growth by creating a low-oxygen environment, sparing healthy cells from chemotherapy damage.
Researchers have identified the interleukin-13 receptor ¬ chain variant 2 (IL13R¢) as a potential target for therapy in glioblastoma multiforme (GBM). Early successes of clinical trials with targeted therapies against IL13R¢ suggest increased survival time for GBM patients.
Researchers developed a new method to detect malignant brain tumors using a handheld Raman scanner, which can identify cancerous cells with high accuracy. The technique has the potential to improve surgical outcomes and reduce tumor recurrence rates.
The Translational Genomics Research Institute has received regulatory approval for a $5 million clinical trial study on glioblastoma. The pilot trial will test new drugs to extend GBM patient survival, while also analyzing genomic data from over 536 past cases and conducting lab tests to measure cell responses.
Glioblastomas are resistant to drug therapy due to epigenetic regulation of EGFR signaling, not altered DNA sequences. This finding suggests a new approach to guiding cancer therapy by analyzing the epigenetic signature of glioblastoma cells.
Scientists have successfully tested a new treatment for aggressive brain cancer, using tiny gold nanoparticles to kill tumour cells. The treatment combines chemotherapy with radiotherapy, targeting cancer cells directly and enhancing the impact of conventional treatments.
Researchers at McGill University have identified SUMO1 as a key player in the proliferation of glioblastoma tumour cells. The study reveals that sumoylation of CDK6 protein stabilizes it, enabling cancer stem cell growth and progression. This breakthrough could lead to targeted therapies for treating brain cancer.